EA201791736A1 - Комбинированная терапия для лечения рака - Google Patents
Комбинированная терапия для лечения ракаInfo
- Publication number
- EA201791736A1 EA201791736A1 EA201791736A EA201791736A EA201791736A1 EA 201791736 A1 EA201791736 A1 EA 201791736A1 EA 201791736 A EA201791736 A EA 201791736A EA 201791736 A EA201791736 A EA 201791736A EA 201791736 A1 EA201791736 A1 EA 201791736A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer treatment
- combined therapy
- cancer
- recurrence
- progression
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562117283P | 2015-02-17 | 2015-02-17 | |
| PCT/US2016/018070 WO2016133903A2 (en) | 2015-02-17 | 2016-02-16 | Combination therapy for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201791736A1 true EA201791736A1 (ru) | 2017-12-29 |
Family
ID=56689146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791736A EA201791736A1 (ru) | 2015-02-17 | 2016-02-16 | Комбинированная терапия для лечения рака |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20180235986A1 (enExample) |
| EP (1) | EP3258965A4 (enExample) |
| JP (3) | JP2018506550A (enExample) |
| CN (1) | CN107249635A (enExample) |
| CA (1) | CA2976696A1 (enExample) |
| EA (1) | EA201791736A1 (enExample) |
| MA (1) | MA41555A (enExample) |
| WO (1) | WO2016133903A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| BR112019000544A2 (pt) | 2016-07-15 | 2019-04-24 | Takeda Pharmaceutical Company Limited | métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática |
| WO2018098348A1 (en) * | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a cd38 inhibitor and methods of use thereof |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| AU2019208102B2 (en) | 2018-01-12 | 2025-10-09 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| CN115403603A (zh) * | 2018-09-14 | 2022-11-29 | 成都奥璟生物科技有限公司 | 一种硼酸酯类药物及其用途 |
| JP2022512722A (ja) * | 2018-10-17 | 2022-02-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下投与を提供する方法 |
| WO2020194241A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses |
| EP3980064A1 (en) | 2019-06-10 | 2022-04-13 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
| JP7428601B2 (ja) * | 2020-06-29 | 2024-02-06 | 株式会社神戸製鋼所 | ガスシールドアーク溶接方法、構造物の製造方法及びシールドガス |
| EP4080515A1 (en) | 2021-04-19 | 2022-10-26 | Roche Diagnostics GmbH | A method for classifying an identification tag on a sample tube containing a sample and an automated laboratory system |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA015584B1 (ru) * | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| CN102961387B (zh) * | 2007-08-06 | 2016-04-27 | 米伦纽姆医药公司 | 蛋白酶体抑制剂 |
| GEP20125599B (en) * | 2007-08-06 | 2012-08-10 | Millennium Pharm Inc | Proteasome inhibitors |
| US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| BR122014008753A2 (pt) * | 2008-06-17 | 2015-12-29 | Millennium Pharm Inc | compostos de éster boronato e composições farmacêuticas dos mesmos |
| LT2621531T (lt) * | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| SG11201506956TA (en) * | 2013-03-13 | 2015-10-29 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
-
2016
- 2016-02-15 MA MA041555A patent/MA41555A/fr unknown
- 2016-02-16 CN CN201680010651.6A patent/CN107249635A/zh active Pending
- 2016-02-16 EP EP16752904.9A patent/EP3258965A4/en not_active Withdrawn
- 2016-02-16 EA EA201791736A patent/EA201791736A1/ru unknown
- 2016-02-16 CA CA2976696A patent/CA2976696A1/en active Pending
- 2016-02-16 JP JP2017542868A patent/JP2018506550A/ja not_active Withdrawn
- 2016-02-16 WO PCT/US2016/018070 patent/WO2016133903A2/en not_active Ceased
- 2016-02-16 US US15/551,093 patent/US20180235986A1/en not_active Abandoned
-
2020
- 2020-12-18 JP JP2020209908A patent/JP2021059564A/ja not_active Withdrawn
-
2021
- 2021-01-21 US US17/154,498 patent/US20210137955A1/en not_active Abandoned
- 2021-08-02 US US17/392,158 patent/US20210369748A1/en not_active Abandoned
-
2022
- 2022-02-25 US US17/680,718 patent/US20220184103A1/en not_active Abandoned
-
2023
- 2023-03-16 US US18/184,918 patent/US20230201227A1/en not_active Abandoned
- 2023-07-14 JP JP2023115987A patent/JP2023130496A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN107249635A (zh) | 2017-10-13 |
| US20180235986A1 (en) | 2018-08-23 |
| JP2021059564A (ja) | 2021-04-15 |
| EP3258965A4 (en) | 2018-08-29 |
| MA41555A (fr) | 2017-12-26 |
| WO2016133903A3 (en) | 2017-01-05 |
| CA2976696A1 (en) | 2016-08-25 |
| JP2023130496A (ja) | 2023-09-20 |
| US20210369748A1 (en) | 2021-12-02 |
| JP2018506550A (ja) | 2018-03-08 |
| EP3258965A2 (en) | 2017-12-27 |
| US20220184103A1 (en) | 2022-06-16 |
| WO2016133903A2 (en) | 2016-08-25 |
| US20210137955A1 (en) | 2021-05-13 |
| US20230201227A1 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791736A1 (ru) | Комбинированная терапия для лечения рака | |
| CY1126855T1 (el) | Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου | |
| PH12019501959A1 (en) | Therapeutic rna | |
| EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
| EP4302835A3 (en) | Methods of treating ovarian cancer | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| EA201790413A1 (ru) | Антитела против tigit | |
| MX379621B (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer | |
| EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
| EA201790737A1 (ru) | Комбинированная терапия | |
| EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
| EA201790180A1 (ru) | Способы и терапевтические комбинации для лечения опухолей | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| EA201791095A1 (ru) | Способ лечения рака | |
| EA201692472A1 (ru) | Соединения для лечения рака мозга | |
| EA201790529A1 (ru) | Новые антитела против mfi2 и способы их применения | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| MX382904B (es) | Combinaciones de fármacos para tratar mieloma múltiple. | |
| MX2018010709A (es) | Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control. | |
| EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы | |
| EA201891968A1 (ru) | Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина |